Expert Interview
A look at the results from Boston Scientific's CHAMPION-AF study evaluating the WATCHMAN FLX™ left atrial appendage closure device as a first-line therapy for stroke risk reduction in patients with atrial fibrillation.
Ticker(s): BSXInstitution: Mount Sinai
- Cardiac electrophysiologist and Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai Hospital.
- Performs 200 Left Atrial Appendage closure procedures per year and implants pacemakers for the treatment of bradycardia over 500 times per year.
- Has authored over 200-peer reviewed scientific publications mainly focused in arrhythmia care.
How are you currently approaching stroke risk reduction in patients with atrial fibrillation, and what factors guide your use of oral anticoagulation versus procedural interventions?
Added By: sara_adminWhat is your interpretation of the CHAMPION-AF data for WATCHMAN FLX™, particularly regarding safety and efficacy outcomes compared to standard oral anticoagulation?
Added By: sara_adminHow do you view the potential role of left atrial appendage closure as a first-line therapy rather than a secondary option for patients unable to tolerate anticoagulation?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Apr 09, 2026
- Call Time
- 03:00 PM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
